Table 1.
♢Targetable antigens in T-cell malignancies and their expression in normal and malignant cells.
| Antigen | Frequency in T-cell malignancies | Expression in normal tissues | Clinical application | References | |
|---|---|---|---|---|---|
| T-ALL/Ly | TCL | ||||
| PAN-T CELL ANTIGENS | |||||
| CD5 | 90% | 85% (PTCL-NOS) | T cells, thymocytes, B-1 cells | Clinical Trial | (15–17) |
| 96% (AITL) | NCT03081910° | ||||
| 26–32% (ALCL) | |||||
| 36% (NK-T) | |||||
| 85% (ATLL) | |||||
| 91% (CTCL) | |||||
| CD7 | >95% | 50% (PTCL-NOS) | T cells, thymocytes | Clinical Trial | (15, 17–21) |
| 57% (AITL) | NK cells | NCT03690011∇ | |||
| 32–54% (ALCL) | NCT02742727± | ||||
| 79% (NK-T) | |||||
| 25% (ATLL) | |||||
| 18% (CTCL) | |||||
| CD3 | 33% | 60–66% (PTCL-NOS) | Mature T cells | (22) | |
| 71% (AITL) | |||||
| 32–40% (ALCL) | |||||
| 36%* (NK-T) | |||||
| 80% (ATLL) | |||||
| 91% (CTCL) | |||||
| ANTIGENS WITH RESTRICTED EXPRESSION | |||||
| CD30 | 17%* | 16% (PTCL-NOS) | Activated T and B cells | Clinical Trial | (22–24) |
| 32–50%* (AITL) | NCT02917083° | ||||
| 93% (ALCL) | NCT02690545° | ||||
| 64%* (NK-T) | NCT03602157° | ||||
| 39% (ATLL) | NCT03383965° | ||||
| 18% (CTCL) | NCT03049449° | ||||
| NCT02958410° | |||||
| TRBC1 | 7–11% | 27% (PTCL-NOS) | ~35% of T cells | NCT03590574° | (20, 25–28) |
| (TCR) | 34% (AITL) | ||||
| 25% (ALCL) | |||||
| CCR4 | ~0% | 34% (PTCL) | Tregs, Th2 and Th17 cells | (29–32) | |
| 88% (ATLL) | Platelets | ||||
| 31–100% (CTCL) | Kidney | ||||
| CD4 | 12% | 60% (PTCL-NOS) | CD4+ T cells | (33, 34) | |
| 86% (AITL) | Some monocytes and | ||||
| 63% (ALCL) | Dendritic cells | ||||
| 29%* (NK-T) | |||||
| 94% (ATLL) | |||||
| 92% (CTCL) | |||||
| CD37 | ~0% | 82% | Mature B cells | (35, 36) | |
| At a low level in plasma cells | |||||
| Low levels in dendritic cells | |||||
*
Only partial positivity observed in malignant cells. ALCL, anaplastic large cell lymphoma; PTCL-NOS, peripheral T cell lymphoma-not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ATLL, adult T-cell lymphoma and leukemia; T-ALL/LBL, T-cell acute lymphoblastic leukemia or lymphoma.
°
Clinical trial status: recruiting.
∇
Clinical trial status: not yet recruiting patients.
±
Clinical trial status: unknown.